StockNews.com initiated coverage on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH – Free Report) (TSE:AUP) in a report released on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the company. Royal Bank of Canada upped their price objective on Aurinia Pharmaceuticals from $11.00 to […]